These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 14653433

  • 1. alpha1-acid glycoprotein in late-life depression: relationship to medical burden and genetics.
    Adeoye OM, Ferrell RE, Kirshner MA, Mulsant BH, Seligman K, Begley AE, Reynolds CF, Pollock BG.
    J Geriatr Psychiatry Neurol; 2003 Dec; 16(4):235-9. PubMed ID: 14653433
    [Abstract] [Full Text] [Related]

  • 2. Double-blind comparison of paroxetine and nortriptyline on the postural stability of late-life depressed patients.
    Laghrissi-Thode F, Pollock BG, Miller MC, Mulsant BH, Altieri L, Finkel MS.
    Psychopharmacol Bull; 1995 Dec; 31(4):659-63. PubMed ID: 8851637
    [Abstract] [Full Text] [Related]

  • 3. Estimating treatment effects from longitudinal clinical trial data with missing values: comparative analyses using different methods.
    Houck PR, Mazumdar S, Koru-Sengul T, Tang G, Mulsant BH, Pollock BG, Reynolds CF.
    Psychiatry Res; 2004 Dec 15; 129(2):209-15. PubMed ID: 15590048
    [Abstract] [Full Text] [Related]

  • 4. Venlafaxine versus nortriptyline in the treatment of elderly depressed inpatients: a randomised, double-blind, controlled trial.
    Kok RM, Nolen WA, Heeren TJ.
    Int J Geriatr Psychiatry; 2007 Dec 15; 22(12):1247-54. PubMed ID: 17562523
    [Abstract] [Full Text] [Related]

  • 5. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
    Otsubo T, Akimoto Y, Yamada H, Koda R, Aoyama H, Tanaka K, Mimura M, Nakagome K, Kamijima K.
    Pharmacopsychiatry; 2005 Jan 15; 38(1):30-5. PubMed ID: 15706464
    [Abstract] [Full Text] [Related]

  • 6. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, Hébert C, Debonnel G.
    Eur Neuropsychopharmacol; 2009 Jul 15; 19(7):457-65. PubMed ID: 19345072
    [Abstract] [Full Text] [Related]

  • 7. Orosomucoid influences the response to antidepressants in major depressive disorder.
    Harley J, Roberts R, Joyce P, Mulder R, Luty S, Frampton C, Kennedy M.
    J Psychopharmacol; 2010 Apr 15; 24(4):531-5. PubMed ID: 19395425
    [Abstract] [Full Text] [Related]

  • 8. Residual cognitive impairment in late-life depression after a 12-month period follow-up.
    Portella MJ, Marcos T, Rami L, Navarro V, Gastó C, Salamero M.
    Int J Geriatr Psychiatry; 2003 Jul 15; 18(7):571-6. PubMed ID: 12833300
    [Abstract] [Full Text] [Related]

  • 9. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D, Bridgman K, Buis C.
    J Psychopharmacol; 2006 Jan 15; 20(1):91-6. PubMed ID: 16204325
    [Abstract] [Full Text] [Related]

  • 10. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M.
    Curr Med Res Opin; 2006 Jul 15; 22(7):1331-41. PubMed ID: 16834832
    [Abstract] [Full Text] [Related]

  • 11. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
    Herrera-Guzmán I, Gudayol-Ferré E, Lira-Mandujano J, Herrera-Abarca J, Herrera-Guzmán D, Montoya-Pérez K, Guardia-Olmos J.
    Psychiatry Res; 2008 Jul 15; 160(1):72-82. PubMed ID: 18501971
    [Abstract] [Full Text] [Related]

  • 12. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, Bertschy G.
    Ther Drug Monit; 2008 Aug 15; 30(4):474-82. PubMed ID: 18641553
    [Abstract] [Full Text] [Related]

  • 13. Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice.
    Rosenberg C, Lauritzen L, Brix J, Jørgensen JB, Kofod P, Bayer LB.
    Psychopharmacol Bull; 2007 Aug 15; 40(1):63-73. PubMed ID: 17285097
    [Abstract] [Full Text] [Related]

  • 14. Cerebral volume measurements and subcortical white matter lesions and short-term treatment response in late life depression.
    Janssen J, Hulshoff Pol HE, Schnack HG, Kok RM, Lampe IK, de Leeuw FE, Kahn RS, Heeren TJ.
    Int J Geriatr Psychiatry; 2007 May 15; 22(5):468-74. PubMed ID: 17357181
    [Abstract] [Full Text] [Related]

  • 15. Substance P in serum and cerebrospinal fluid of depressed patients: no effect of antidepressant treatment.
    Deuschle M, Sander P, Herpfer I, Fiebich BL, Heuser I, Lieb K.
    Psychiatry Res; 2005 Jul 15; 136(1):1-6. PubMed ID: 16024091
    [Abstract] [Full Text] [Related]

  • 16. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
    Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I.
    JAMA; 1998 Jan 28; 279(4):287-91. PubMed ID: 9450712
    [Abstract] [Full Text] [Related]

  • 17. Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities.
    Kishino S, Nomura A, Itoh S, Nakagawa T, Takekuma Y, Sugawara M, Furukawa H, Todo S, Miyazaki K.
    Eur J Clin Pharmacol; 2002 Dec 28; 58(9):621-8. PubMed ID: 12483455
    [Abstract] [Full Text] [Related]

  • 18. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec 28; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 19. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression.
    Mihaljevic Peles A, Bozina N, Sagud M, Rojnic Kuzman M, Lovric M.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug 01; 32(6):1439-44. PubMed ID: 18550244
    [Abstract] [Full Text] [Related]

  • 20. The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease.
    Dobkin RD, Menza M, Bienfait KL, Gara M, Marin H, Mark MH, Dicke A, Tröster A.
    J Neuropsychiatry Clin Neurosci; 2010 Aug 01; 22(2):188-95. PubMed ID: 20463113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.